Progressive vs Non-Progressive Onset of Chronic GVHD After ATG Prophylaxis Is Highly Predictive of Outcome  by Jones, David et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341 S327437
Progressive vs Non-Progressive Onset of Chronic GVHD
After ATG Prophylaxis Is Highly Predictive of Outcome
David Jones 1, Muhd Zakaria 1, Maggie Yang 1, Loree Larratt 2,
Robert Turner 2, Chris Brown 1, Nizar Bahlis 1,
Mary Lynn Savoie 1, Andrew Daly 1, Michelle Geddes 1,
Jan Storek 1, Nancy Zacarias 1, Peter Raymond Duggan 1,
Diana Quinlan 1, Douglas Stewart 1, James A. Russell 1. 1 Blood
and Bone Marrow Transplant Program, Tom Baker Cancer
Centre/Foothills Hospital, Calgary, AB, Canada; 2 Cross Cancer
Institute, Edmonton, AB, Canada
The NIH chronic graft versus host disease (cGVHD) consensus
statement emphasizes the importance of distinguishing
acute from cGVHD based on clinical features rather than
time. The proposed assessment of cGVHD severity appears to
be prognostically important, but the relevance of categories
and type of onset remains controversial. We retrospectively
analyzed a homogeneously treated population of 600
patients transplanted between 1999-2010 with ﬂudarabine
50 mg/m2 daily X 5, IV busulfan 3.2 mg/kg daily x 4, ATG
(Thymoglobulin, Genzyme - total dose of 4.5 mg/kg). An
additional 287 patients (48%) received additional TBI 200cGy
x 2. In this cohort, 245 patients (47%) had non-progressive
cGVHD (NP-cGVHD) arising either de novo (n ¼ 221) or after
stopping primary immunosuppression (n ¼ 24). In 71
patients (12%) progressive cGVHD (P-cGVHD) arose during
systemic therapy for grade II-IV acute GVHD and 284 (41%)
had no cGVHD. Patient and transplant factors were similar
across all groups. Median followup was 84 (range 22- 161)
months. The 5-year non-relapse mortality was 40% for
patients with P-cGVHD compared with 11% for NP-cGVHD (P
< .0001) and 12% for no cGVHD (P < .0001). Patients with no
cGVHD had more relapse (38%) than those with P-cGVHD
(28%,P ¼ .02) and P-cGVHD (27%,P ¼ .002). Overall survival
for patients with no cGVHDwas 61% vs 50% for P-cGVHD (P¼
.005) and 69% for NP-cGVHD (P ¼ .02). Disease free survival
was 54% vs 43% (P ¼ .003) and 65% (P ¼ .003), respectively.
The median time on systemic immunosuppression for the
174 NP-cGVHD patients (71%) who required treatment was
273 days versus 398 days for all patients with P-cGVHD (p ¼
ns). In conclusion, we propose that this simple means of
classifying cGVHD is highly predictive of important trans-
plant outcomes. It remains important both to prevent acute
GVHD (and thus P-cGVHD) and yet take advantage of the
graft-vs-malignancy effect conferred by NP-cGVHD.438
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Institute, Oakland, CAGraft-versus-host disease (GVHD) is characterized by cyto-
kine and chemokine dysregulation that predicts and also
contributes to disease severity. Intermediates in sulfur amino
acid (SAA) metabolism are known to modulate cytokines
implicated in GVHD, such as TNF-a and IL-2. In this ﬁrst
report, plasma and hepatic SAAs and other amino acid
metabolite concentrations were sequentially proﬁled using
redox metabolomics assay, in experimental allogeneic bone
marrow transplantation (Allo-BMT)models and compared to
syngeneic (Syn) BMT. At day +4, prior to increase in plasma
TNF-a and subsequent GVHD histopathological changes,
a signiﬁcant decline in both plasma and hepatic glutathione
(GSH) concentrations occurred resulting in a more oxidized
redox potential in Allo BMT (Balb/C B6), relative to Syn BMT
(B6Thy1.1 B6) mice. The plasma free GSH concentrations in
allogeneic mice were signiﬁcantly lower (w65%; P < .005)
when compared to Syn BMT controls and were accompanied
byw 3 fold increase (P¼ .012) in plasma GSSG. Paradoxically,
the plasma concentration of total cysteine, which is the rate-
limiting substrate for GSH synthesis, was signiﬁcantly higher
in Allo BMT versus Syn BMT mice at day +10 suggesting that
loss in GSH was not due to substrate limitation. Signiﬁcant
difference in the GSSG/GSH ratio was also noted in Allo /
GVHD+ compared to Allo/GVHD- in un-irradiated paternal to
F1 hybrid transplantation model (B6  B6D2F1), indicating
that GSH depletion was a metabolic event associated with
GVHD, and not a consequence of conditioning regimen
(0.3150  0.06007 vs 17.00  4.907, respectively, p¼0.0145).
At day+10, metabolomic proﬁle was able to segregate Allo/
GVHD+ from Allo/GVHD- based on hepatic total GSH, free
GSH and total cystinylglycine concentration. The plasma
TNF-a elevation lagged behind redox changes with no
signiﬁcant difference detected in Syn-BMT and Allo-BMT
group at day +4. Hepatic GCLC mRNA abundance, regulated
by Nrf2 transcription factor, was decreased by w50% (P <
.0001) at day +4 and further declinedw80% by Day +10 (P <
.0004), in Allo BMT compared to Syn BMT. Interestingly,
hepatic nuclear Nrf2 and TNF-a concentrations at Day +10
were inversely correlated (r2¼0.8,P ¼ .01) in Allo-BMT.
Modulation of GSH in mixed lymphocyte culture using GSH
depleting agents, buthionine sulfoximine and diethyl mal-
eate, increased TNF-a expression in CD4 T cells compared to
untreated controls (P < .001). These experiments show the
utility of redox metabolomics to identify novel putative
biomarkers in GVHD.
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